The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection

Zezhong Liu  
Fudan university

Wei Xu  
Fudan university

Shuai Xia  
Fudan university

Chenjian Gu  
Fudan university

Xinling Wang  
Fudan university

Qian Wang  
Fudan university

Jie Zhou  
Fudan university

Yanling Wu  
Fudan university

Xia Cai  
Fudan university

Di Qu  
Fudan university

Tianlei Ying  
Fudan university

Youhua Xie  
Fudan university

Lu Lu  
Fudan university

Zhenghong Yuan  
Fudan university

Shibo Jiang  
shibojiang@fudan.edu.cn  
Fudan university
Abstract

The pandemic of COVID-19 caused by SARS-CoV-2 has posed serious threats to global health and economy, thus calling for the development of safe and effective vaccines. The receptor-binding domain (RBD) in the spike protein of SARS-CoV-2 is responsible for its binding to ACE2 receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that immunization of mice with a candidate subunit vaccine consisting of SARS-CoV-2 RBD and Fc fragment of human IgG, as an immunopotentiator, elicited high titer of RBD-specific antibodies with robust neutralizing activity against both pseudotyped and live SARS-CoV-2 infections. The mouse antisera could also effectively neutralize infection by pseudotyped SARS-CoV-2 with several natural mutations in RBD and the IgG extracted from the mouse antisera could also show neutralization against pseudotyped SARS-CoV and SARS-related coronavirus (SARSr-CoV). Vaccination of human ACE2 transgenic mice with RBD-Fc could effectively protect mice from the SARS-CoV-2 challenge. These results suggest that SARS-CoV-2 RBD-Fc has good potential to be further developed as an effective and broad-spectrum vaccine to prevent infection of the current SARS-CoV-2 and its mutants, as well as future emerging SARSr-CoVs and re-emerging SARS-CoV.

Background

The outbreaks of severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV) in 2002/2003 and those of middle east respiratory syndrome (MERS) caused by MERS coronavirus (MERS-CoV) in 2012 have highlighted the high zoonotic potential of emerging coronaviruses\(^\text{1, 2}\). The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus 2019 (2019-nCoV)\(^\text{3}\), which was also denoted as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\(^\text{4}\), or human coronavirus 2019 (HCoV-19)\(^\text{5}\), has resulted in more than 17 million confirmed cases and 0.66 million deaths in 216 countries, areas or territories (https://www.who.int/), endangering the global public health and economy and thus calling for the development of effective vaccines to protect at-risk populations.

Currently, more than 150 COVID-19 vaccines are under development at different stages\(^\text{6-9}\). Especially, a number of COVID-19 vaccines' phase 1/2 clinical trials have been completed, including the adenovirus-vectored vaccines (Ad5-nCoV and ChAdOx1 nCoV-19) from CanSino\(^\text{10}\) and Oxford University/AstraZeneca\(^\text{11}\), respectively; the mRNA vaccines (mRNA-1273 and BNT162b1) from Moderna\(^\text{12}\) and Pfizer/BioNTech\(^\text{13}\), respectively; and the inactivated vaccines (PiCoVacc and BBIBP-CorV) from Sinovac\(^\text{14}\) and Beijing Institute of Biological Products\(^\text{15}\), respectively (https://biorender.com/covid-vaccine-tracker/). Generally speaking, all these vaccines could induce antibodies specific for spike (S) protein and receptor-binding domain (RBD), which neutralized pseudotyped and live SARS-CoV-2 infection. Some reports have shown that the neutralizing antibody titers are strongly correlated with RBD-binding IgG concentration\(^\text{16}\). However, most of these vaccines developed specifically against SARS-CoV-2 infection may not be effective to prevent infection by SARS-CoV-2 with significant mutations in its spike (S) protein and the SARS-CoV and SARSr-CoVs.
Coronavirus S protein, a class I viral fusion protein consisting of S1 and S2 subunits, plays pivotal roles in virus binding, fusion and entry, and it serves as an important target for the development of vaccines and neutralizing antibodies\textsuperscript{17}. For example, most of the mRNA, DNA, and viral vector-based COVID-19 vaccines contain the gene encoding SARS-CoV-2 S protein\textsuperscript{10,12,18,19}. The receptor-binding domain (RBD) in S1 of SARS-CoV and SARS-CoV-2 recognizes and binds to the receptor ACE2 on the host cells and causes the conformational changes of S2 that result in virus fusion with and entry into the host cell for replication\textsuperscript{20,21}.

Our previous studies have shown that SARS-CoV RBD contains multiple conformation-dependent epitopes and is able to induce high-titer neutralizing antibodies\textsuperscript{22-25}, suggesting that RBD is one of the most important targets for the development of SARS vaccine. We have also demonstrated that Fc fragment of human IgG in the RBD-based vaccine, RBD-Fc, can act as an important immunopotentiator to enhance the immunogenicity of RBD\textsuperscript{25-27}. SARS-CoV RBD-Fc could induce antibodies in rabbits and mice with highly potent neutralizing activity and inhibitory activity to block the binding between S1 and the host receptor ACE2\textsuperscript{24}. Importantly, SARS-CoV RBD-Fc could induce long-term neutralizing antibody responses that effectively protect the vaccinated mice against SARS-CoV infection\textsuperscript{25}.

Using a similar approach, we have designed a recombinant subunit vaccine candidate, RBD-Fc, which contains RBD in S1 of SARS-CoV-2 and Fc fragment of human IgG. We found that mice immunized with the recombinant SARS-CoV-2 RBD-Fc protein produced high titer of RBD-specific antibodies, which could potently neutralize infection of SARS-CoV-2 without or with mutations and show neutralization activity against SARS-CoV and SARSr-CoVs. Therefore, this RBD-Fc-based vaccine showed high potential to be further developed as a highly effective COVID-19 vaccine.

Results

Recombinant RBD protein of SARS-CoV-2 exhibited good conformation and antigenicity. To obtain immunogen for immunization of mice, we constructed an expression vector encoding SARS-CoV-2 RBD and Fc fragment of human IgG (Figure 1a). After expression in Expi293F cells and purification with affinity chromatography, we characterized the RBD-Fc protein in both boiled and unboiled conditions using SDS-PAGE. As shown in Figure 1b, a single strong band with a molecular weight of \~60 kDa was noted in the boiled condition and one of \~120 kDa in the non-boiled condition, suggesting that the well-expressed RBD-Fc with high purity had formed a dimer via the Fc in the non-boiled condition. The recombinant RBD-Fc protein expressed in high yields, and the purification was high.

Using ELISA to investigate the binding activity between RBD-Fc and human ACE2 (hACE2), we found that the RBD-Fc could effectively bind to the hACE2 in a dose-dependent manner with a 50% effective dose (EC50) of 0.27 \textmu M (Figure 1c). These results indicate that RBD-Fc exhibits proper conformation and functionality and that it can serve as an excellent immunogen.
RBD-Fc induced strong RBD-specific IgG antibody responses in mice. Three different doses of RBD-Fc (10, 5 and 2.5 µg, respectively) were used to immunize mice in order to optimize the dose of antigen that could sufficiently induce antibody response. The mice were vaccinated subcutaneously three times at 14-day intervals, and the sera were collected at 7 days after each boost (Figure 2a). The geometric mean titer (GMT) of RBD-specific IgG in sera was detected with ELISA using the protein of RBD-His, rather than RBD-Fc, to coat the plates in order to eliminate the influence of antibodies against Fc. For the sera collected from mice on day 21 post-1\textsuperscript{st} immunization with 2.5, 5, and 10 µg of RBD-Fc, the GMTs of SARS-CoV-2 RBD-specific antibody IgG are 32,254, 64,508 and 117,713, respectively (Figure 2b and 2c), and those of SARS-CoV-2 S1-specific antibody IgG are 3,200, 10,159 and 19,577, respectively (Figure 2d and 2e), while the sera from mice treated with PBS exhibited only background level of the signal. For the sera collected on day 35 post-1\textsuperscript{st} immunization with 2.5, 5, and 10 µg of RBD-Fc, the GMTs of RBD-specific antibody IgG were increased to 315,420, 378,800 and 546,323, respectively, while those of SARS-CoV-2 S1-specific antibody IgG were increased to 126,267, 262,645, and 454,914, respectively (Figure 2f-2i). These results suggest that immunization of mice 2 to 3 times with RBD-Fc at 2.5 - 10 µg could elicit similarly strong RBD-specific antibody responses.

RBD-Fc elicited robust neutralizing antibody responses in mice against pseudotyped and live SARS-CoV-2 infection. To assess whether the sera contains neutralizing antibodies against SARS-CoV-2 infection, we developed a pseudovirus (PsV) expressing S protein of SARS-CoV-2, which could simulate the SARS-CoV-2 virion to enter and infect the target cell without replication\textsuperscript{28-30}. The sera collected from mice immunized with 2.5, 5 and 10 µg of RBD-Fc at day 21 post-1\textsuperscript{st} immunization potently neutralized SARS-CoV-2 PsV infection in Huh-7 cells with geometric mean 50% neutralization titers (NT50) of 864, 1,389, and 1,795, respectively (Figure 3a). The geometric mean NT50s of the sera were increased to 1,965, 8,179, and 7,166, respectively, at day 35 post-1\textsuperscript{st} immunization (Figure 3b). These results suggest that immunization of mice with 5 µg RBD-Fc is able to elicit highly potent neutralizing antibody responses.

We then developed a competition ELISA assay to detect whether SARS-CoV-2 RBD-specific antisera could block the interaction between SARS-CoV-2 RBD and hACE2. As shown in Figure 3c, antibodies in the antisera from mice immunized with RBD-Fc at day 35 post-1\textsuperscript{st} immunization could significantly inhibit the binding of SARS-CoV-2 RBD to hACE2, compared with the sera from mice treated with PBS, indicating that RBD-Fc-induced antibodies could neutralize SARS-CoV-2 PsV infection by blocking the binding of RBD in S protein on the surface of SARS-CoV-2 to hACE2.

Next, we tested the neutralization activity of the antisera collected from mice immunized with 10 µg RBD-Fc at day 35 post-1\textsuperscript{st} immunization against live SARS-CoV-2 infection in Vero-E6 cells using an immunofluorescence assay\textsuperscript{31}. After the addition of the antisera at a dilution of 1:2,700 or 1:8,100, we found that the expression of SARS-CoV-2 N protein in the cells was almost completely, or partially, suppressed, respectively (Figure 3d). Then, we further tested the viral RNA in the cell supernatant using an RT-qPCR assay. The results showed that the antisera could inhibit live SARS-CoV-2 infection in a dose-
dependent manner with an NT50 of 10,523 (Figure 3e), consistent with the result from the immunofluorescence assay.

Recently, hACE2 transgenic (hACE2-Tg) mice were used for the development of an animal model of SARS-CoV-2 infection. We, therefore, immunized hACE2-Tg mice with the same immunization strategy to investigate the protective effects of vaccination \textit{in vivo} (Figure 2f). The hACE2-Tg mice were vaccinated with 5 µg RBD-Fc three times and then challenged with SARS-CoV-2 intranasally. The lungs were collected at 4 days post-challenge to test their virus titer. As shown in Figure 2g, the viral RNA was not detected in the lungs from RBD-Fc-immunized mice, while relatively high viral RNA copies were detected in the lungs from PBS-treated mice.

To investigate whether the neutralizing antibody response in mice immunized with RBD-Fc could maintain at high level for a longer period of time, we tested the neutralization activity of pooled sera from mice immunized with 10 µg RBD-Fc at 3 months post-1\textsuperscript{st} immunization. The results showed that pooled sera could also effectively neutralize the SARS-CoV-2 PsV infection with the NT50 of 2,013 (Figure S1). These results indicate that the RBD-Fc vaccine is able to induce relative long-term neutralizing antibody responses.

**RBD-Fc-induced antibodies inhibited SARS-CoV-2 S-mediated cell-cell fusion.** Subsequently, we adapted a cell-cell fusion assay by utilizing 293T effector cells expressing SARS-CoV-2 S protein and EGFP and Huh-7 target cells expressing human ACE2 to test whether RBD-specific antisera could block SARS-CoV-2 S protein-mediated cell-cell fusion. We found that all antisera from mice vaccinated with 2.5, 5 or 10 µg at a dilution of 1:100 could completely inhibit SARS-CoV-2 S-mediated cell-cell fusion, while the sera from the PBS-treated mice showed no significant inhibitory effect (Figure 4a). The calculated geometric mean IT50 (50% inhibition titers) of the sera collected from the mice vaccinated with 2.5, 5 and 10 µg at day 35 post-1\textsuperscript{st} immunization were 724 (95% CI, 404 to 1294), 1,787 (95% CI, 734 to 4,348) and 1,503 (95% CI, 555 to 4071), respectively. Consistent with the results from SARS-CoV-2 PsV inhibition assay, the 5 µg group showed inhibitory activity against cell-cell fusion similar to that of the 10 µg group, but much better than that from the 2.5 µg group, suggesting, again, that 5 µg is the optimal dose of RBD-Fc for immunization. Collectively, these results show that immunization of mice with 5 µg of RBD-Fc can elicit high titers of RBD-specific antibodies to neutralize infection of pseudotyped and live SARS-CoV-2 and inhibit SARS-CoV-2 S-protein-mediated membrane fusion.

**SARS-CoV-2 RBD-Fc could induce cross-neutralization of antibodies against infection of pseudotyped SARS-CoV-2 mutants, SARS-CoV and SARSr-CoV.** SARS-CoV-2 has been undergoing continuous mutations in its S protein, especially in the RBD region, which may render the virus resistant to neutralizing antibodies induced by the COVID-19 vaccines currently under development. To determine whether the mutations in RBD are resistant to the neutralizing antibodies induced by RBD-Fc, we constructed 7 SARS-CoV-2 PsVs with single natural mutation in RBD of SARS-CoV-2 S protein and used them to analyze their sensitivity to the neutralization activity of mouse antisera. All 7 mutants could be...
effectively neutralized by the pooled sera collected from mice immunized with 10 µg RBD-Fc at day 35 post-1st immunization with NT50 of >3,000 (Figure 5a-5h).

Given that the RBD of SARS-CoV-2 has 74.7% and 75.2% amino acid sequence identity to the RBD of SARS-CoV and bat-SARSr-CoV-WIV1, respectively (Figure 6a), we determined whether SARS-CoV-2 RBD-Fc-induced antibodies could cross-react with RBD of SARS-CoV using ELISA. As shown in Figures 6b and 6c, the sera collected from mice immunized with 10 µg RBD-Fc at day 35 post-1st immunization could effectively bind to RBD of SARS-CoV in a dose-dependent manner with IgG GMT of 51,200. We then purified the total IgG from the pooled sera collected from mice immunized with 10 µg RBD-Fc at day 35 post-1st immunization to test its neutralization activity against SARS-CoV-2 PsV infection. We found that total SARS-CoV-2 IgG could significantly neutralize infection of SARS-CoV-2 PsV (Figure 6d), SARS-CoV PsV (Figure 6e), and bat-SARSr-CoV PsV (Figure 6f), respectively, although the neutralizing activity against SARS-CoV-2 PsV turned out to be more potent than that against SARS-CoV PsV and bat-SARSr-CoV PsV. These results serve as additional evidence that SARS-CoV-2 RBD-Fc has the potential to be developed as a broad-spectrum vaccine to prevent infection by lineage B betacoronaviruses, including SARS-CoV-2 that has caused the current COVID-19 pandemic, as well as SARS-CoV and bat-SARSr-CoV that may cause the future coronavirus disease outbreaks.

Identification of the linear epitopes in the SARS-CoV-2 RBD domain. To investigate whether RBD-Fc-vaccinated mice could produce antibodies targeting linear epitopes in the SARS-CoV-2 RBD domain, we synthesized a group of peptides spanning the RBD region in S protein (residues 314-543). Each peptide contained 20 amino acids with 10 residues overlapping with the adjacent peptides. These peptides were precoated in a chip. The results revealed that four linear peptides in the SARS-CoV-2 RBD domain could react with the antisera (Figure 7a). To further confirm the reactions and quantify the binding capacity, we coated the four peptides on ELISA plates to detect antibody-peptide binding in sera. Some sera induced by RBD-Fc showed higher binding capacity to the four linear peptides (Figure 7b-7e). Particularly, peptide S464-483 could strongly react with the antisera collected from mice vaccinated with 2.5, 5 or 10 µg at day 35 post-1st immunization, demonstrating that S464-483 is an immunodominant linear epitope in the SARS-CoV-2 RBD domain.

We then tested whether these peptides could block the neutralizing activity of antibodies in mouse antisera. The results showed that the neutralization was not significantly affected by these peptides at the concentration as high as 10 µg/ml, while RBD-Fc at 0.078 - 0.312 µg/ml could effectively block the neutralization activity of RBD-specific antibody (Figure 7f). We then tested whether these peptides could inhibit SARS-CoV-2 PsV infection and found that none of these peptides could significantly inhibit SARS-CoV-2 PsV infection, whereas the RBD-Fc protein could effectively inhibit SARS-CoV-2 PsV infection in a dose-dependent manner (Figure 7g). These results suggest that most SARS-CoV-2 RBD-specific neutralizing antibodies recognize conformational, but not linear, epitopes. Some peptides containing linear epitopes may induce non-neutralizing antibodies, consistent with the finding of SARS-CoV RBD-specific neutralizing antibodies34. When designing a COVID-19 vaccine, the epitope with the ability to
induce non-neutralizing antibody or neutralizing antibody with antibody-dependent enhancement (ADE) effect should be masked with a glycan probe as previously described.35

Discussion

Development of a safe and effective COVID-19 vaccine that can elicit neutralizing antibodies capable of preventing SARS-CoV-2 infection has been the global goal of controlling the COVID-19 epidemic. In consideration of the severity of the COVID-19 pandemic, several candidate vaccines have promptly entered into clinical trials. Although these candidate vaccines showed promise in induction of neutralizing antibody and T cell responses, it is still elusive whether these vaccines can indeed protect the vaccinated people from infection by SARS-CoV-2, particularly those with significant mutations in S protein, in phase III clinical trials or in future application. Compared with other vaccine types, recombinant protein-based subunit vaccines are largely considered to be safer.36, 37 Since RBD contains the dominant neutralizing epitopes in the S protein, a vaccine consisting of RBD, rather than full-length S protein, is expected to effectively induce neutralizing antibodies and minimize the production of non-neutralizing antibodies.

It has been reported that the vast majority of neutralizing antibodies against SARS-CoV-2 target the RBD.38 Tai W et al have recently shown that the lipid nanoparticle-encapsulated RBD-based mRNA COVID-19 vaccine elicited in mice highly potent neutralizing antibodies (NT50: ~10,000) against SARS-CoV-2 pseudovirus infection. These antibodies could also cross-neutralize infection of pseudotyped SARS-CoV strains Tor2 and GD03 from humans, and SZ3 from palm civets, indicating that this RBD-based mRNA vaccine is able to induce neutralizing antibodies against both SARS-CoV-2 and SARS-CoV infection.39 Zhang N et al have also demonstrated that an LNP-encapsulated SARS-CoV-2 RBD-based mRNA vaccine (ARCoV) is able to induce in mice and NHPs both neutralizing antibody response and Th1-biased cellular response, resulting in full protection against challenge of a mouse-adapted SARS-CoV-2 strain.40 More recently, Yang J et al have demonstrated that RBD-based COVID-19 vaccine could induce much higher titer of neutralizing antibody (NT50: ~2,400) than S protein (NT50: ~300) and S1 subunit (NT50: ~1,100).41 Moreover, a disulfide-linked SARS-CoV-2 RBD dimer was demonstrated to enhance the neutralizing antibody titer compared to the RBD monomer.36 The RBD dimer might have several advantages for increasing immunogenicity, such as increasing molecular weight, better stimulation of B cells and exposure of the immunodominant neutralizing epitopes.36 Different from the disulfide-linked dimer approach, we conjugated the human IgG Fc fragment to the C-terminus of SARS-CoV-2 RBD to allow it to form RBD-Fc dimer, which showed excellent binding capacity to hACE2 (Figure 1c). In addition, the Fc fragment in RBD-based vaccine can serve as an immunopotentiator to enhance the immunogenicity of the vaccine since it promotes interaction of the vaccine with Fc receptor on the antigen-presenting cells.42-44 Although several RBD-based vaccines containing no Fc described above are effective in eliciting potent neutralizing antibody responses and protective immunity in different animal models, it is still elusive whether these neutralizing antibodies could maintain at high level for a longer period of time. Addition of Fc fragment to the RBD-based vaccine can prolong the half-life of the
immunogen\(^45\) and promote the long-term neutralizing antibody responses. For example, our previous study has demonstrated that the titer of neutralizing antibodies in the sera of mice immunized with RBD-Fc-based SARS-CoV vaccine is able to maintain at high level (NT50: 580) for at least 6 months, which is much higher than that of neutralizing antibodies required for sterilizing immunity or full protection (NT50: 189)\(^46\). Most recently, we have assessed the titer of neutralizing antibodies in the sera of mice immunized with SARS-CoV-2 RBD-Fc vaccine for 3 months and found that the neutralizing antibody titer was still at high level (NT50: 2,013, Figure S1), suggesting that RBD-Fc vaccine can elicit long-term neutralizing antibody responses.

In view of the severity of the COVID-19 pandemic, application of the lowest dose of vaccine and fewest boosters to produce sufficient immune response would be desirable. By injecting 2.5, 5 or 10 µg RBD-Fc to mice, we were surprised to find that 5 µg RBD-Fc is sufficient to induce high titer of RBD-specific antibodies able to neutralize SARS-CoV-2 PsV infection with geometric mean NT50 of 8,179 and inhibit SARS-CoV-2 S-mediated cell-cell fusion with geometric mean IT50 of 1,787, which are similar to that of mice immunized with 10 µg RBD-Fc, but significantly better than mice immunized with 2.5 µg RBD-Fc. These results had an instructive significance for the design of the optimal dose of RBD-based vaccine against SARS-CoV-2 infection. We also found that mouse antisera could block RBD binding to ACE2, demonstrating that the sera contain antibodies that can specifically bind to the key sites in RBD responsible for binding ACE2.

To date, many amino acid mutations, especially in RBD, in SARS-CoV-2 S protein have been identified and reported, raising concerns about whether the developed vaccines could also be useful against these SARS-CoV-2 mutants. Notably, most of the reported RBD-based vaccine candidates have not been tested for their neutralization activities against the emerging SARS-CoV-2 mutants. We thus successfully constructed 7 RBD mutants of SARS-CoV-2 PsV with detectable infectivity and used them to test the neutralization activity. Our results showed that the neutralization activity of the RBD-Fc-induced pooled antisera was not influenced by these natural mutations in RBD of SARS-CoV-2 PsV with NT50 >3,000. Especially, a previous study has demonstrated that the RBD with V367F mutation had enhanced binding affinity to ACE2\(^33\). However, the RBD-Fc-induced antisera could also effectively neutralize infection of SARS-CoV-2 PsV with V367F mutation in RBD with NT50 of 6,532.

Another important goal of designing COVID-19 vaccine is to make the vaccine with broad-spectrum neutralizing activity and protective efficacy against lineage B betacoronaviruses, including SARS-CoV-2, SARS-CoV and SARSr-CoV that may cause future emerging or reemerging coronavirus diseases. Although the sequence identity of S proteins between SARS-CoV-2 and SARS-CoV is high, whether the SARS-CoV convalescent sera could cross-neutralize SARS-CoV-2 remains controversial. For example, one recent study has demonstrated that sera from the recovered SARS patents and SARS-CoV RBD-immunized mice and rabbits could strongly react with RBDs of both SARS-CoV and SARS-CoV-2 and neutralize both SARS-CoV and SARS-CoV-2 infection\(^47\), while another study reported that SARS convalescent plasma could not neutralize SARS-CoV-2 infection, even though it showed strong cross-reactivity to SARS-CoV-2\(^48\). Another
study has shown that the monoclonal antibody S309 identified from the B cells of SARS survivor using SARS-CoV-2 S protein could bind to the RBDs of SARS-CoV-2 and SARS-CoV and, thus, cross-neutralize infection of both viruses. These studies implied that a SARS-CoV-2 RBD-based vaccine might induce cross-neutralizing antibodies against SARS-CoV and SARS-CoV, although, the cross-neutralization activity of the antibodies elicited by most of the reported RBD-based vaccine candidates has not been shown. Here we found that the antibody in the antisera induced by SARS-CoV-2 RBD-Fc vaccine exhibited cross-neutralization activity against infection of pseudotyped SARS-CoV and a bat pseudotyped SARSr-CoV WIV1. The titer of cross-neutralizing antibodies is not high; however, it is promising for the development of RBD-based broad-spectrum vaccines against lineage B betacoronavirus infection. Consistent with the results from the pseudovirus neutralization assay, serum neutralization activity against live SARS-CoV-2 further confirmed the strong inhibitory effects with significant neutralization, even with serum diluted to 1:8,100. Most importantly, we also identified that the RBD-based vaccine could effectively protect hACE2-Tg mice against SARS-CoV-2 challenge.

Identification of linear immunodominant sites in RBD to discover the neutralizing or non-neutralizing epitopes is crucial for designing vaccines. We found that four peptides derived from the RBD region of SARS-CoV-2 (S344-363, S454-473, S464-483 and S524-543) could react with antibodies in the antisera from mice immunized with RBD-Fc. Interestingly, one recently published study has also reported several linear immunodominant sites in the RBD of SARS-CoV-2, including S330-349, S375-394, S450-469, S480-499, and S522-646, which partially overlap with those identified in our study. None of these peptides could significantly block the neutralization antibodies in the RBD-Fc-induced antisera, suggesting that the neutralizing epitopes in SARS-CoV-2 RBD are conformational, not linear, which is consistent with those in SARS-CoV RBD. We will use these peptides to immunize mice and test their antisera for SARS-CoV-2 neutralizing activity. If they do not neutralize or even enhance SARS-CoV-2 infection, we will optimize the RBD-based vaccine by covering these non-neutralizing immunodominant sites with glycosylation in order to design more effective and safer RBD-based vaccines.

In summary, we have designed and developed an RBD-Fc-based vaccine that can induce highly potent neutralizing antibody responses against infection of pseudotyped SARS-CoV-2, SARS-CoV and bat SARSr-CoV-WIV1, and live SARS-CoV-2. It is effective to protect hACE2-Tg mice from SARS-CoV-2 challenge. All these results suggest that this RBD-Fc-based vaccine has a great potential to be further developed for use in humans to protect against infection of SARS-CoV-2, as well as SARS-CoV and SARSr-CoVs, which may cause future outbreaks of emerging and reemerging coronavirus diseases.

Methods

Cells, reagents, plasmids, viruses and animals. HEK-293T, Huh-7 and Vero-E6 cells were obtained from the American Type Culture Collection (ATCC). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, Gibco, USA). Freund's complete and incomplete adjuvants were bought from Sigma (USA). The luciferase system reagents, including cell lysis solution and substrate, were from Promega (USA). Plasmids containing pcDNA3.1-
SARS-2-S, pcDNA3.1-SARS-S, pcDNA3.1-WIV1-S, pAAV-IRES-EGFP-SARS-2-S and pNL4-3.Luc.R-E were maintained in our laboratory. Six-week-old specific-pathogen-free (SPF) Balb/c mice were bought from Beijing Vital River Laboratory Animal Technology Co. (Beijing, China). Eight-week-old SPF hACE2 transgenic mice were from the Institute of Laboratory Animal Science, Peking Union Medical College, China. All the experiments related to animals were carried out according to institutional regulations (approval number 20190221-070; approval date 21 February 2019).

**Protein expression and purification.** Genes encoding residues 319-532 of SARS-CoV-2 (GenBank accession number: QHD43416.1) spike protein fused with the genes of Fc or His in its N-terminal were inserted into the plasmid of PcDNA3.1. The recombinant expression plasmids were transfected into Expi293F cells, and then the cells were cultured for three days. After that, cell culture supernatants were collected and purified using affinity chromatography. The purified recombinant proteins were concentrated by ultrafiltration using Amicon Ultra-10 filters (Millipore, USA). Finally, the purified recombinant proteins were analyzed using SDS-PAGE. Briefly, 10% Tris-glycine SDS-PAGE was used to separate the proteins, and then the proteins in the gel were stained using Coomassie Brilliant Blue to visualize the protein lines.

**Mouse vaccination.** Three doses of RBD-Fc (2.5, 5, and 10 µg) were diluted using PBS. Freund's complete adjuvant was emulsified with the proteins or PBS at a volume ratio of 1:1 for the first immunization. After the prime vaccination by subcutaneous injection, the mice were boosted twice using Freund's incomplete adjuvant, mixing RBD-Fc or PBS subcutaneously at two-week intervals. The mice were bled at 7 days post each boost, and the sera were separated and inactivated at 56 °C for 30 min.

**ELISA.** ELISA was used to detect the binding between RBD-Fc and human ACE2. RBD-Fc protein (2 µg/ml) was coated on the ELISA plates at 4°C overnight. Then the plates were blocked using blocking buffer (PBST containing 5% BSA) at 37 °C for 2h. A series of concentrations of human ACE2 protein was added to the plate and incubated at 37 °C for 2 h. After 4 times of washing using PBST, rabbit anti-human ACE2-specific antibody (Sino Biological, Beijing, China) was added to the plate and incubated for 2 h at 37 °C. Subsequently, HRP-conjugated goat anti-rabbit IgG (Dako, Denmark) was added to the plates and incubated for 1 h at 37 °C. The reaction was finally visualized by adding 3,3',5,5'-Tetramethylbenzidine (TMB) and then stopped by H2SO4. A microplate reader (Infinite M200PRO, Switzerland) was used to collect the data at the absorbance of 450 nm.

The antibody response in the mice immunized with RBD-Fc was performed by coating RBD-His protein (1 µg/ml) on ELISA plates, followed by adding serially diluted SARS-CoV-2 RBD-Fc immunized mouse sera and HRP-conjugated goat anti-mouse IgG (Dako). Titers were expressed as the reciprocal of the last dilution exhibiting \( A_{450} \geq 2.1 \)-fold of the background values.

A blocking ELISA was used to detect whether the immunized mouse sera could block the binding between SARS-CoV-2 RBD and hACE2. ELISA plates precoated with RBD-His were incubated with the sera at 37 °C for 1 h first before hACE2 protein was added. Then, the protocol was done as described above.
Neutralization of pseudotyped SARS-CoV-2, SARS-CoV and WIV1 infection. Production of the SARS-CoV-2 PsV, SARS-CoV PsV and WIV1 PsV was conducted as previously described\(^{28,51}\). Briefly, the plasmids of PNL4–3.luc.RE and pcDNA3.1- SARS-CoV-2-S / pcDNA3.1-SARS-CoV / pcDNA3.1-WIV1 were cotransfected into HEK293T cells using a transfection reagent of VigoFect (Vigorous Biotechnology, China). The supernatant containing pseudotyped particles was collected at 60 h post-transfection. The pseudotyped viruses were preserved at -80 °C until use.

The plasmid of pcDNA3.1-SARS-CoV-2-S was used as a template to replace the relative amino acids using a site mutation kit (Yeasen, China). Then, the SARS-CoV-2 mutant PsVs were produced as described above.

Sera neutralization activities in the pseudovirus system were assessed as previously described\(^{28,50}\). Briefly, 1×10\(^4\) /well of Huh-7 cells were seeded into a 96-well plate. After 8 h of culture, one of the PsVs (SARS-CoV-2 PsV, SARS-CoV PsV or WIV1 PsV) was mixed with a serial dilution of sera and incubated at 37 °C for 0.5 h. Then, the mixtures were transferred into Huh-7 cells, and the supernatant was replaced with fresh DMEM containing 2% FBS after 12 h. The cells were continuously cultured for 48 h, and then the luciferase activity was detected using a Firefly Luciferase Assay Kit (Promega, Madison, WI, USA).

Cell-cell fusion assay. Neutralization activities of the sera were evaluated using S- mediated cell-cell fusion assay as previously described with a simple modification\(^{28,29}\). Briefly, HEK293T cells were transfected with the plasmid of pAAV-IRES-EGFP- SARS-2-S or pAAV-IRES-EGFP. When the EGFP was effectively expressed in the effector cells (293T/S/GFP), the mixtures of the effector cells (1×10\(^4\) cells/well) and the diluted sera from mice treated with RBD-Fc or PBS were added into the target Huh-7 cells (2×10\(^4\) cells/well). After incubation for 4 h, the fused and unfused cells in five randomly selected fields were counted using an inverted fluorescence microscope (Nikon Eclipse Ti-S).

Extraction and purification of mouse total IgG. Total IgG from 10 µg RBD-Fc- treated mice pooled sera or PBS-treated mice pooled sera was purified using protein G affinity chromatography (GE Healthcare, USA). The eluted IgG was concentrated by ultrafiltration using Amicon Ultra-30 filters (Millipore). The neutralization assay was conducted as described above.

Live SARS-CoV-2 neutralization assay in BSL3. The live SARS-CoV-2 neutralization assay was done as previously described with simple modification\(^{31}\). Vero- E6 cells were seeded in a 96-well plate (10000 cells/well) at 24 h before infection. The sera were serially diluted and mixed with 0.1 MOI SARS-CoV-2 at 37 °C for 0.5 h, and then the mixtures were added into the cells and further cultured for 48 h. The supernatants were collected to conduct the RT-qPCR assay. The cells were fixed by 4% paraformaldehyde to conduct the immunofluorescence assay. For the RT-qPCR assay, total RNA in the supernatants was extracted using Trizol LS (Thermo) first. Then, RT- qPCR was performed using a One-Step PrimeScrip RT-PCR Kit (Takara, Japan) with primers and probe as follows: SARS-CoV-2-ORF1ab-F: CCCTGTGGGTTTTACACTTAA, SARS-CoV-2-ORF1ab-R: ACGATTGTGCATCAGCTGA, SARS-CoV-2-ORF1ab-probe: 5’-FAM-CCGTCTCGGTATGTAAGTTATGG-BHQ1-3’. For the immunofluorescence
assay, the cells were treated with 0.1% Triton X for 15 min at room temperature and then blocked by 3% BSA. After that, the anti-N antibody (1:1000) was added to the cells and incubated at 4 °C overnight. Finally, Alexa Fluor donkey anti-mouse IgG 488-labeled antibody (Thermo) was added to the cells and incubated at 37 °C for 1 h. After staining with DAPI, the cells were imaged with fluorescence microscopy.

**hACE2 transgenic mouse challenge experiment.** A total of six hACE2 mice were randomly assigned to two groups, and each group contained three mice. The hACE2 mice immunization strategy was done as described above. After the third immunization, the mice were challenged with $10^5$ TCID50 SARS-CoV-2 intranasally. After 4 days of infection, the mice were sacrificed, and the lungs were collected and homogenized in Trizol (Takara). Next, the total RNA in the lungs was extracted. RT-qPCR was used to determine SARS-CoV-2 virus titer in the lungs.

**Pepscan assay.** A total of 20 peptides were synthesized by GL biochem LTD (Shanghai, China). The peptide sequences were as follows: S314-333: QTSNFRVQPTESIVRFNPIT; S324-343: ESIVRFPNITNLCPFGEVFN; S334-353: NLCPFGEVFNATRFASVYA; S344-S363: ATRFASVAYWNRKISNCVA; S354-373: NKRISNCVADYSVLNSAS; S374-393: FSTFKCYGVSTKLNDLCFT; S384-S403: PTKLNDLCFTNYADSFVIR; S394-413: NVYADSFVIRGDENVRIAPG; S414-433: QTGKIADYNYKLPDDFTGCV; S424-443: KLPDDFTGCVIAWNSNLD; S434-S453: IAWNSNLDKVGNNYNYLY; S444-S463: KVGGNYNYLYRLFRKSNLKLP; S454-473: RLFKSNLKPFE; S464-483: FERDSEIQAGSTPCNGV; S474-493: QAGSTPCNGVEFGNCFPLQ; S484-503: EGFNCYFPLQSYGFQPTNGV; S494-513: SYGFQPTNGVGYQPYRVVVL; S5044-S523: GYQPYRVVVLSFELLHAPAT; S514-533: SFELLHAPATVC; S524-543: VCPKSTNLVKNKCVNFN.

The peptide blocking neutralization assay was done as described above with simple modification. Briefly, 4 µg/ml of total IgG extracted from the pooled sera induced by 10 µg RBD-Fc were incubated with increasing concentration of peptides at 37 °C for 30 min. After that, the mixture of peptides and antibody was incubated with the SARS-CoV-2 PsV. Then, the mixture of peptides, antibody and SARS-CoV-2 PsV was added to the Huh-7 cells. Luciferase activity was detected using a Firefly Luciferase Assay Kit (Promega).

**Statistics.** All statistical analyses were carried out with GraphPad Prism software. P<0.05 was considered significant. *P<0.05; **P<0.01; ***P<0.001. Student's unpaired two-tailed t-test was used to compare the binding capacity to ACE2 between RBD-Fc-induced sera and PBS-induced sera. One-way ANOVA was used to compare the neutralization activity between IgG induced by RBD-Fc and IgG induced by PBS and live SARS-CoV-2 neutralization between RBD-Fc-induced sera and PBS-induced sera.
This study was supported by grants from National Natural Science Foundation of China (82041025 to S.J., 81822045 to L.L.). Development Programs for COVID-19 of Shanghai Science and Technology Commission (Grant No. 20431900401)

Author contributions

S.J., Z.Y. and L.L. designed the experiments. Z.L., W.X., S.X., C.G., X.W., Q.W., J.Z., Y.W., and X.C. performed the experiments. Z.L., D.Q., T.Y, X.Y., L.L., Z.Y. and S.J. analyzed the data and wrote this manuscript.

Competing interests

The authors declare no competing interests.

References

1. Lu G, Wang Q, Gao Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. *Trends Microbiol* 23, 468-478 (2015).

2. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol* 14, 523-534 (2016).

3. Wu F, et al. A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265-269 (2020).

4. Gorbalenya AE, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 5, 536-544 (2020).

5. Jiang S, et al. A distinct name is needed for the new coronavirus. *Lancet* 395, 949-949 (2020).

6. Thanh Le T, et al. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov* 19, 305-306 (2020).

7. Mullard A. COVID-19 vaccine development pipeline gears up. *Lancet* 395, 1751-1752 (2020).

8. Lurie N, Saville M, Hatchett R, Halton Developing Covid-19 Vaccines at Pandemic Speed. *New Engl J Med* 382, 1969-1973 (2020).

9. The Lancet. Global governance for COVID-19 vaccines. *Lancet* 395, 1883 (2020).
10. Zhu F, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* **395**, 1845-1854 (2020).

11. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*, S0140-6736(20)31604-4 (2020).

12. Jackson LA, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*, NEJMoa2022483 (2020).

13. Mulligan MJ, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. Preprint at https://doi.org/10.1101/2020.06.20.159715 (2020).

14. Gao Q, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science* **369**, 77-81 (2020).

15. Wang H, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. *Cell*, in press https://doi.org/10.1016/j.cell.2020.06.008. (2020).

16. Sahin U, et al. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. Preprint at https://doi.org/10.1101/2020.07.17.20140533 (2020).

17. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. *Nat Rev Microbiol* **7**, 226-236 (2009).

18. Smith TRF, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. *Nat Commun* **11**, 2601 (2020).

19. van Doremalen N, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Preprint at https://doi.org/10.1101/2020.05.13.093195 (2020).

20. Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat *Nature* **579**, 270-273 (2020).

21. Xia S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Research* **30**, 343-355 (2020).

22. Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. *Front Microbiol* **11**, 298 (2020).
23. Jiang S, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. *Expert Rev Vaccines* **11**, 1405-1413 (2012).

24. He Y, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochem Biophys Res Commun* **324**, 773-781 (2004).

25. Du L, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. *Vaccine* **25**, 2832-2838 (2007).

26. He Y, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochem Biophys Res Commun* **324**, 773-781 (2004).

27. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. *J Immunol* **176**, 6085-6092 (2006).

28. Xia S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res* **30**, 343-355 (2020).

29. Xia S, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cell Mol Immunol* **17**, 765-767 (2020).

30. Xia S, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Sci Adv* **5**, eaav4580 (2019).

31. Gu C, et al. Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 Preprint at https://doi.org/10.1101/2020.04.30.071290 (2020).

32. Bao L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature*, 10.1038/s41586-020-2312-y (2020).

33. Ou J, et al. Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein. Preprint at https://doi.org/10.1101/2020.03.15.991844 (2020).

34. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. *J Immunol* **174**, 4908-4915 (2005).

35. Du L, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. *Nat Commun* **7**, 13473 (2016).
36. Dai L, et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell*, S0092-8674(20)30812-6 (2020).

37. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. *Expert Rev Vaccines* **13**, 761-774 (2014).

38. Burton DR, Walker Rational Vaccine Design in the Time of COVID-19. *Cell Host Microbe* **27**, 695-698 (2020).

39. Tai W, et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. *Cell Res.* 1038/s41422-020-0387-5 (2020).

40. Zhang N-N, et al. A thermostable mRNA vaccine against COVID-19. *Cell*, in press https://doi.org/10.1016/j.cell.2020.07.024 (2020).

41. Yang J, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. *Nature* 10.1038/s41586-020-2599-8 (2020).

42. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. *J Immunol* **176**, 6085-6092 (2006).

43. Nimmerjahn F, Ravetch Fc gamma receptors as regulators of immune responses. *Nat Rev Immunol* **8**, 34-47 (2008).

44. Du L, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and coli cells elicits potent neutralizing antibody and protective immunity. *Virology* **393**, 144-150 (2009).

45. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. *Curr Opin Biotech* **22**, 868-876 (2011).

46. Du L, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. *Vaccine* **25**, 2832-2838 (2007).

47. Zhu Y, et al. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Preprint at https://doi.org/10.1101/2020.04.20.052126 (2020).

48. Wang Y, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. *J Clin Invest* **138759** (2020).

49. Pinto D, et al. Structural and functional analysis of a potent sarbecovirus neutralizing antibody. Preprint at https://doi.org/10.1101/2020.04.07.023903 (2020).
50. Du L, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. *Nat Commun* **7**, 13473 (2016).

51. Liu Z, et al. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. *Virol Sin* **35**, 340-343 (2020).

**Figures**

**Figure 1**

Preparation and identification of the immunogen. (a) Construction of the RBD protein fused with human IgG Fc fragment. (b) SDS-PAGE to visualize the RBD proteins in boiled or non-boiled conditions. (c) Evaluation of the binding capacity between RBD-Fc and hACE2.
Figure 2

Preparation and identification of the immunogen. (a) Construction of the RBD protein fused with human IgG Fc fragment. (b) SDS-PAGE to visualize the RBD proteins in boiled or non-boiled conditions. (c) Evaluation of the binding capacity between RBD-Fc and hACE2.
Figure 3

Neutralization activity of sera from day 21 and day 35 against SARS-CoV-2 PsV. (a) The NT50s for each mouse at day 21. (b) The NT50s for each mouse at day 35. (c) Mouse antisera inhibited hACE2 binding to SARS-CoV-2 RBD. (d) Detection of SARS-CoV-2 N protein expression in cells treated with sera using immunofluorescence assay. (e) Detection of SARS-CoV-2 virus titer in the cell supernatant using RT-qPCR assay. Each point represents means ± s.e.m. from triplicate samples. (f) The immunization and challenge strategy of hACE2 mice. (g) The virus titers in the lungs of hACE2 mice. * P<0.05; ** P<0.01; *** P<0.001.
Figure 4

Mouse antisera inhibited SARS-CoV-2 S protein-mediated cell-cell fusion. (a) SARS-CoV-2 S protein-mediated cell-cell fusion inhibited by sera from day 35 at a dilution of 100. (b) The IT50s of sera from day 35 against SARS-CoV-2 S protein-mediated cell-cell fusion.

Figure 5
Neutralization activities of sera from day 35 against SARS-CoV-2 mutant PsVs. (a-h) The inhibitory effects of pooled sera from 10 µg RBD-Fc-immunized mice and pooled sera from PBS-treated mice against SARS-CoV-2 mutant PsVs V341I (a), F342L (b), V367F (c), R408I (d), A435S (e), G476S (f), V483A (g) and wild type (h). Each point represents means ± s.e.m. from triplicate samples.

Figure 6

Cross-neutralization activity against SARS-CoV and SARSr-CoV. (a) The RBD amino acid sequence of SARS-CoV-2, SARS-CoV and bat-SARSr-CoV-WIV1. (b) and (c) Detection of SARS-CoV RBD-specific IgG in different dilutions of sera (b) and the IgG titer to SARS-CoV RBD (c). (d-f) Neutralization effects of total IgG from the indicated sera against SARS-CoV-2 (d), SARS-CoV (e) and WIV1 (f). Each point represents means ± s.e.m. from triplicate samples. * P<0.05; ** P<0.01; *** P<0.001.
Cross-neutralization activity against SARS-CoV and SARSr-CoV. (a) The RBD amino acid sequence of SARS-CoV-2, SARS-CoV and bat-SARSr-CoV-WIV1. (b) and (c) Detection of SARS-CoV RBD-specific IgG in different dilutions of sera (b) and the IgG titer to SARS-CoV RBD (c). (d-f) Neutralization effects of total IgG from the indicated sera against SARS-CoV-2 (d), SARS-CoV (e) and WIV1 (f). Each point represents means ± s.e.m. from triplicate samples. * P<0.05; ** P<0.01; *** P<0.001.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- FigS1.png